Multiple Myeloma Antibody Combinations Clinical Trials Insight
22 May 2024
ImmunotherapyDrug Approval
“Currently 65 Antibodies Combinations Are Approved For Various Cancer Treatments”
The treatment landscape for multiple myeloma ailment is a rapidly evolving field with ongoing research and clinical trials aimed at better understanding these conditions and developing effective therapies. Multiple myeloma is a group of hematological malignancies disorders characterized by the abnormalities in plasma cells, a type of white blood cell. With the rising incidence as well as prevalence of multiple myeloma year by year led to the development of novel combination therapies which can target these ailments. In the recent year, finding for the need of novel treatments led to the discovery of antibody combinations used for the treatment of multiple myeloma.
The research and development of antibody combinations for the treatment of multiple myeloma begin when the monoclonal antibodies (mAbs), daratumumab (Darzalex) in addition elotuzumab (Empliciti), have aided to expand the treatment options for multiple myeloma and thereby led to great improvement in patient outcome. The mechanism used by these antibodies is to target the signaling lymphocytic activation molecule family 7 (SLAMF7)/ CD319 or CD38 that are frequently overexpressed in multiple myeloma cells. On the account of that reason, several antibody combinations, like Sarclisa (isatuximab-irfc), in combination with pomalidomide (Pomalyst) and dexamethasone, Sarclisa in combination with carfilzomib (Kyprolis) and dexamethasone, and Darzalex Faspro, Kyprolis, and Dexamethasone were approved in the 2020 and 2021 for the treatment of adult patients with relapsed or refractory multiple myeloma.
Download Research Insight:
Since the discovery of antibody combinations involved for the treatment of multiple myeloma, there has been significant research into understanding the mode of action of antibody has been completed. Studies have focused on developing treatments that can prevent the abnormal aggregation of plasma cells or mitigate its toxic effects. Succeeding the approval of antibody combination, many clinical as well as translational research are being initiated in the arena with the intention to develop and innovative and advanced antibody combination treatment regimen which will aid to provide treatment for numerous patients suffering from multiple myeloma malignancies.
Currently, numerous clinical researches are ongoing in the realm, few of which have reached the late stage of development that are being conducted by various pharma companies and hospitals such as Sanofi, Pfizer, Wuerzburg University Hospital, ClinAssess GmbH, Arbeitsgemeinschaft medikamentoese Tumortherapie, SWOG Cancer Research NetworkCancer Research Network, National Cancer Institute (NCI)Cancer Institute (NCI), ECOG-ACRIN Cancer Research GroupCancer Research Group, Eastern Cooperative Oncology Group, European Myeloma Network, Karyopharm Therapeutics, GlaxoSmithKline, Janssen Research & Development, Alexion Pharmaceuticals etc.
Apart from the involvement of various stakeholders from the giant pharma companies, the pipeline for sphere of antibody combinations for the treatment of multiple myeloma consist of monoclonal and bispecific antibodies targeting immune checkpoint receptors like anti PD-1, anti PD-L1, anti CTLA-4 along with BCMA, CD3, OX40, CD38, GPRC5D directed CD3 bispecific antibodies, interleukin- 6 receptor mAbsinterleukin- 6 receptor mAbs along with gamma secretase inhibitor. Presence of different types of therapeutic agents with antibody illustrates that the realm of antibody combinations to treat multiple myeloma is growing and it is expected that multiple novel combinations will be launch in the upcoming years.
The vista of antibody combination therapy for the treatment of multiple myeloma is expanding at an incredible gait on the account of the rising growth of antibody combinations in the commercial market along with augmenting partnerships, increasing research, investments and collaborations in the domain. For instance, in January 2024, a researcher at Penn State Cancer InstituteCancer Institute based in the US, stated that the bispecific antibodies plays a significant role for the treatment of in hematologic malignancies, particularly multiple myeloma. Despite the fact that chimeric antigen receptor (CAR)-T cell therapy have made surplus benefits to patients, yet the role of bispecific antibodies becomes progressively apparent in the difficult-to-treat population with multiple myeloma patients.
Antibody combinations represent a significant breakthrough in the management of multiple myeloma. By targeting the key pathway and receptors such as SLAMF7/ CD319 or CD38 that are involved in progression of multiple myeloma, the therapeutic approach offer an effective and convenient way to increase effectiveness and reduce the side effects along with drug resistances. Despite some challenges, Antibody combinations clenches great promise in transforming the lives of those suffering from multiple myeloma, providing a beacon of aspiration to numerous individuals suffering from multiple myeloma. As research continues, the use of antibody combination therapies may become more refined and accessible treatment, further improving their role in multiple myeloma management.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.